Drug Trial Radar · NCT06101134
A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations
Last checked: Nov 19, 2026Latest source record: Sep 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
100
Actual
Start
Nov 6, 2023
Primary completion
Apr 10, 2025
Study completion Dec 21, 2026
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Oct 26, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the patient's preference for nivolumab subcutaneous (SC) or nivolumab + relatlimab fixed-dose combination (FDC) SC and provide patient experience data by route of administration. This study will also generate safety data which will further characterize the safety profile of patients switching the route of administration from intravenous (IV) to SC.
Conditions
- Melanoma
Interventions
relatlimab+nivolumabDrug
Specified dose on specified days
relatlimab+nivolumab+rHuPH20Drug
Specified dose on specified days
nivolumabDrug
Specified dose on specified days
nivolumab+rHuPH20Drug
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Evaluable Participants That Prefer SC Route of Administration Using the Patient Experience and Preference Questionnaire (PEPQ) (Question 7) After Cycle 4 Day 1 DoseTime frame: Cycle 4 Day 1 (each cycle consist of 4 weeks)
Locations
31 sites in 5 countries. Site status is shown where the registry gives one.
Local Institution - 0007
Anchorage, Alaska
Local Institution - 0013
Phoenix, Arizona
Local Institution - 0010
San Francisco, California
Local Institution - 0034
Atlanta, Georgia
Local Institution - 0032
Edgewood, Kentucky
Local Institution - 0028
Albuquerque, New Mexico
Local Institution - 0037
Edmonds, Washington
Local Institution - 0036
Issaquah, Washington
Local Institution - 0030
Seattle, Washington
Local Institution - 0005
Concepción, Chile
Local Institution - 0015
Las Condes, Santiago Metropolitan, Chile
Local Institution - 0023
Holargos, Athens, Greece
Local Institution - 0008
Piraeus, Greece
Local Institution - 0033
Thessaloniki, Greece
Local Institution - 0019
Thessaloniki, B, Greece
Local Institution - 0014
Athens, I, Greece
Local Institution - 0029
Marousi, I, Greece
Local Institution - 0026
Naples, Italy
Local Institution - 0017
Bergamo, BG, Italy
Local Institution - 0035
Meldola, FC, Italy
Local Institution - 0018
Milan, MI, Italy
Local Institution - 0012
Padova, PD, Italy
Local Institution - 0021
Roma, RM, Italy
Local Institution - 0004
Torino, TO, Italy
Local Institution - 0020
Badalona, Spain
Local Institution - 0027
Cantabria, Spain
Local Institution - 0003
San Pedro Alcántara, Málaga, Spain
Local Institution - 0006
Seville, Spain
Local Institution - 0011
Barcelona, B, Spain
Local Institution - 0022
Barcelona, B, Spain
Local Institution - 0009
Cartagena, MU, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.